Methadone withdrawal when starting an antiretroviral regimen including nevirapine

Pharmacotherapy

Volumn 19, Issue 4 I, 1999, Pages 471-472

  Heelon, Mark W ^a,c   Meade, Lauren B ^b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; METHADONE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TRANSFORMATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PAIN;

EID: 0032957797     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.6.471.31046     Document Type: Article

References (6)

1. Anonymous. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Ann Intern Med 1998;128:1079-1100.
2. Micromedex Inc. Drug Information: drug evaluation monographs; nevirapine, vol 99, exp 3-99. In: Gelman CR, Rumack BH, Hutchison TA, eds. Drugdex system. Englewood, CO: Micromedex.
3. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW. The pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996.
4. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9(2):365-73.
5. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32(3):194-209.
6. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24(5):475-90.